RU2017135541A - Гетероциклические амины и их применения - Google Patents
Гетероциклические амины и их применения Download PDFInfo
- Publication number
- RU2017135541A RU2017135541A RU2017135541A RU2017135541A RU2017135541A RU 2017135541 A RU2017135541 A RU 2017135541A RU 2017135541 A RU2017135541 A RU 2017135541A RU 2017135541 A RU2017135541 A RU 2017135541A RU 2017135541 A RU2017135541 A RU 2017135541A
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- imidazo
- optionally substituted
- amino
- piperazin
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 6
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 claims 5
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 claims 5
- -1 (6-cyanoimidazo [1,2-a] pyridin-2-yl) amino Chemical group 0.000 claims 4
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 3
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- UXIXQKWFZMRQAY-UHFFFAOYSA-N 1-[4-[[2-[(6-pyridin-3-ylimidazo[1,2-a]pyridin-2-yl)amino]pyridin-4-yl]methyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CC1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=NC=CC=2)=C1 UXIXQKWFZMRQAY-UHFFFAOYSA-N 0.000 claims 1
- UVNOZNSJQYLLSG-UHFFFAOYSA-N 1-[4-[[2-[(6-pyridin-4-ylimidazo[1,2-a]pyridin-2-yl)amino]pyridin-4-yl]methyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CC1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=CN=CC=2)=C1 UVNOZNSJQYLLSG-UHFFFAOYSA-N 0.000 claims 1
- HJIXHJQFJCYQFZ-UHFFFAOYSA-N 2-[[4-(hydroxymethyl)pyridin-2-yl]amino]imidazo[1,2-a]pyridine-6-carbonitrile Chemical compound OCC1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C#N)=C1 HJIXHJQFJCYQFZ-UHFFFAOYSA-N 0.000 claims 1
- CQSGRBXJPFLJTQ-UHFFFAOYSA-N 2-[[4-(pyrrolidin-1-ylmethyl)pyridin-2-yl]amino]imidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C=1N2C=C(C#N)C=CC2=NC=1NC(N=CC=1)=CC=1CN1CCCC1 CQSGRBXJPFLJTQ-UHFFFAOYSA-N 0.000 claims 1
- HTTORECBYPSUCQ-UHFFFAOYSA-N 2-methoxy-1-[4-[2-[(6-pyridin-4-ylimidazo[1,2-a]pyridin-2-yl)amino]pyridin-4-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)COC)CCN1C1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=CN=CC=2)=C1 HTTORECBYPSUCQ-UHFFFAOYSA-N 0.000 claims 1
- FQWGCMSZNAOHDT-UHFFFAOYSA-N 6-(1h-pyrazol-4-yl)-n-[4-(pyrrolidin-1-ylmethyl)pyridin-2-yl]imidazo[1,2-a]pyridin-2-amine Chemical compound C=1C=NC(NC=2N=C3C=CC(=CN3C=2)C2=CNN=C2)=CC=1CN1CCCC1 FQWGCMSZNAOHDT-UHFFFAOYSA-N 0.000 claims 1
- NNYGUJKGXRYTKL-UHFFFAOYSA-N 6-pyridin-3-yl-n-[4-(pyrrolidin-1-ylmethyl)pyridin-2-yl]imidazo[1,2-a]pyridin-2-amine Chemical compound C=1C=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=NC=CC=2)=CC=1CN1CCCC1 NNYGUJKGXRYTKL-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 206010065452 Angiodermatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- JLFXNCTUAAAIKM-UHFFFAOYSA-N [2-[(6-pyridin-3-ylimidazo[1,2-a]pyridin-2-yl)amino]pyridin-4-yl]methanol Chemical compound OCC1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=NC=CC=2)=C1 JLFXNCTUAAAIKM-UHFFFAOYSA-N 0.000 claims 1
- XNNLWBHHLXXJGS-UHFFFAOYSA-N [2-[(6-pyridin-4-ylimidazo[1,2-a]pyridin-2-yl)amino]pyridin-4-yl]methanol Chemical compound OCC1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=CN=CC=2)=C1 XNNLWBHHLXXJGS-UHFFFAOYSA-N 0.000 claims 1
- SQLFUDFJDSKYCD-UHFFFAOYSA-N [2-[[6-(1h-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-yl]amino]pyridin-4-yl]methanol Chemical compound OCC1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C2=CNN=C2)=C1 SQLFUDFJDSKYCD-UHFFFAOYSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- HAEAXHNPMCKGNW-UHFFFAOYSA-N n-[4-(4-methylsulfonylpiperazin-1-yl)pyridin-2-yl]-6-(1h-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-amine Chemical compound C1CN(S(=O)(=O)C)CCN1C1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C2=CNN=C2)=C1 HAEAXHNPMCKGNW-UHFFFAOYSA-N 0.000 claims 1
- SMBZKUOVUIECEC-UHFFFAOYSA-N n-[4-(4-methylsulfonylpiperazin-1-yl)pyridin-2-yl]-6-pyridin-4-ylimidazo[1,2-a]pyridin-2-amine Chemical compound C1CN(S(=O)(=O)C)CCN1C1=CC=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=CN=CC=2)=C1 SMBZKUOVUIECEC-UHFFFAOYSA-N 0.000 claims 1
- LYNMJHLIBHMSCM-UHFFFAOYSA-N n-[4-(piperazin-1-ylmethyl)pyridin-2-yl]-6-(1h-pyrazol-4-yl)imidazo[1,2-a]pyridin-2-amine Chemical compound C=1C=NC(NC=2N=C3C=CC(=CN3C=2)C2=CNN=C2)=CC=1CN1CCNCC1 LYNMJHLIBHMSCM-UHFFFAOYSA-N 0.000 claims 1
- YQNMCHMOOBVYAQ-UHFFFAOYSA-N n-[4-(piperazin-1-ylmethyl)pyridin-2-yl]-6-pyridin-4-ylimidazo[1,2-a]pyridin-2-amine Chemical compound C=1C=NC(NC=2N=C3C=CC(=CN3C=2)C=2C=CN=CC=2)=CC=1CN1CCNCC1 YQNMCHMOOBVYAQ-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D269/00—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00
- C07D269/02—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00 having the hetero atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (35)
1. Соединение, представленное формулой (IV):
или его соль, сложный эфир, амид, или пролекарство,
где X представляет собой N или CR5', где R5' выбирают из водорода, галогена, OR6, необязательно замещенного C1-С6 алкила, необязательно замещенного C1-С6 галогеналкила, необязательно замещенного C1-С6 гетероалкила, необязательно замещенного C1-С6 галогенгетероалкила, необязательно замещенного C1-С6 алкенила и необязательно замещенного C1-С6 алкинила;
R1 выбран из водорода, галогена, OR6, CN, NR7R8, CH2OR6, CH2NR7R8, необязательно замещенного C1-С6 алкила, необязательно замещенного C1-С6 галогеналкила, необязательно замещенного C1-С6 алкенила, необязательно замещенного C1-С6 алкинила, необязательно замещенного C1-С6 гетероалкила, CO2R6, CONR7R8, SO3R6 и SO2NR7R8; и
R2 и R3 независимо выбраны из водорода, галогена, OR6, NR7R8, необязательно замещенного C1-С6 алкила, необязательно замещенного C1-С6 галогеналкила, необязательно замещенного C1-С6 алкенила, необязательно замещенного C1-С6 алкинила и необязательно замещенного C1-С6 гетероалкила.
2. Соединение по п. 1, где X представляет собой N.
3. Соединение по п. 1, где соединение выбрано из группы, состоящей из
6-(1Н-пиразол-4-ил)-N-(4-(пирролидин-1-илметил)пиридин-2-ил)имидазо[1,2-а]пиридин-2-амина,
2-((4-(гидроксиметил)пиридин-2-ил)амино)имидазо[1,2-а]пиридин-6-карбонитрила,
(S)-трет-бутил-3-(2-((6-цианоимидазо[1,2-а]пиридин-2-ил)амино) изоникотинамидо)пирролидин-1-карбоксилата,
(S)-2-((6-цианоимидазо[1,2-а]пиридин-2-ил)амино)-N-(пирролидин-3-ил)изоникотинамида,
2-((4-(пирролидин-1-илметил)пиридин-2-ил)амино)имидазо[1,2-а]пиридин-6-карбонитрила,
6-(пиридин-3-ил)-N-(4-(пирролидин-1-илметил)пиридин-2-ил)имидазо[1,2-а]пиридин-2-амина,
1-(4-((2-((6-(пиридин-4-ил)имидазо[1,2-а]пиридин-2-ил)амино)пиридин-4-ил)метил)пиперазин-1-ил)этанона,
1-(4-((2-((6-(пиридин-3-ил)имидазо[1,2-а]пиридин-2-ил)амино)пиридин-4-ил)метил)пиперазин-1-ил)этанона,
(2-((6-(пиридин-4-ил)имидазо[1,2-а]пиридин-2-ил)амино)пиридин-4-ил)метанола,
N-(4-(пиперазин-1-илметил)пиридин-2-ил)-6-(пиридин-4-ил)имидазо[1,2-а]пиридин-2-амина,
1-(4-((2-((6-(1Н-пиразол-4-ил)имидазо[1,2-а]пиридин-2-ил)амино)пиридин-4-ил)метил)пиперазин-1-ил)этанона,
N-(4-(пиперазин-1-илметил)пиридин-2-ил)-6-(1Н-пиразол-4-ил)имидазо[1,2-а]пиридин-2-амина,
(2-((6-(1Н-пиразол-4-ил)имидазо[1,2-а]пиридин-2-ил)амино)пиридин-4-ил)метанола,
N-(4-(4-(метилсульфонил)пиперазин-1-ил)пиридин-2-ил)-6-(пиридин-4-ил)имидазо[1,2-а]пиридин-2-амина,
2-метокси-1-(4-(2-((6-(пиридин-4-ил)имидазо[1,2-а]пиридин-2-ил)амино)пиридин-4-ил)пиперазин-1-ил)этанона,
N-(4-(4-(метилсульфонил)пиперазин-1-ил)пиридин-2-ил)-6-(1H-пиразол-4-ил)имидазо[1,2-а]пиридин-2-амина,
6-(5-метил-1Н-пиразол-4-ил)-N-(4-(4-(метилсульфонил)пиперазин-1-ил)пиридин-2-ил)имидазо[1,2-а]пиридин-2-амина и
(2-((6-(пиридин-3-ил)имидазо[1,2-а]пиридин-2-ил)амино)пиридин-4-ил)метанола.
4. Фармацевтическая композиция, обладающая ингибирующей активностью в отношении к ассоциированной с рецептором интерлейкина 1 киназы 1 (IRAK-1) и ассоциированной с рецептором интерлейкина 1 киназы 4 (IRAK-4), содержащая соединение по любому из пп. 1-3 и фармацевтически приемлемый носитель.
5. Способ лечения нарушения, чувствительного к ингибированию передачи сигнала, опосредованной ассоциированной с рецептором интерлейкина 1 киназой, включающий введение нуждающемуся в этом субъекту эффективного количества соединения по любому из пп. 1-3.
6. Способ по п. 5, где указанное нарушение представляет собой воспалительное нарушение.
7. Способ по п. 6, где указанное воспалительное нарушение выбрано из группы, состоящей из остеоартрита, ревматоидного артрита, рассеянного склероза, язв роговицы, увеита и воспалительного заболевания кишечника.
8. Способ по п. 5, где указанное нарушение представляет собой нарушение кожи.
9. Способ по п. 8, где указанное нарушение кожи выбрано из группы, состоящей из дерматита, эозинофилии кожи, красного плоского лишая, крапивницы, псориаза, зуда, ангиодерматита, хронических язв кожи, конъюктивита, васкулита и эритемы.
10. Способ по п. 5, где указанное нарушение представляет собой респираторное расстройство.
11. Способ по п. 10, где указанное респираторное расстройство выбрано из группы, состоящей из астмы, ринита, хронического обструктивного заболевания легких, бронхита, полипоза носа, заложенности носа, экзогенного аллергического альвеолита, пневмосклероза и кашля.
12. Способ по п. 5, где указанное нарушение выбрано из группы, состоящей из диабета, ожирения, аллергического заболевания, рака и сепсиса.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41568510P | 2010-11-19 | 2010-11-19 | |
US61/415,685 | 2010-11-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013124101A Division RU2632900C2 (ru) | 2010-11-19 | 2011-11-18 | Гетероциклические амины и их применение |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2017135541A true RU2017135541A (ru) | 2019-02-08 |
RU2017135541A3 RU2017135541A3 (ru) | 2020-11-26 |
Family
ID=45094285
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013124101A RU2632900C2 (ru) | 2010-11-19 | 2011-11-18 | Гетероциклические амины и их применение |
RU2017135541A RU2017135541A (ru) | 2010-11-19 | 2011-11-18 | Гетероциклические амины и их применения |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013124101A RU2632900C2 (ru) | 2010-11-19 | 2011-11-18 | Гетероциклические амины и их применение |
Country Status (14)
Country | Link |
---|---|
US (5) | US9266874B2 (ru) |
EP (3) | EP2730564B1 (ru) |
JP (3) | JP6005050B2 (ru) |
KR (2) | KR20180099933A (ru) |
CN (2) | CN108864151A (ru) |
ES (1) | ES2672203T3 (ru) |
HK (1) | HK1252165A1 (ru) |
HU (1) | HUE037860T2 (ru) |
MX (3) | MX344521B (ru) |
PL (1) | PL2730564T3 (ru) |
PT (1) | PT2730564T (ru) |
RS (1) | RS57375B1 (ru) |
RU (2) | RU2632900C2 (ru) |
WO (1) | WO2012068546A1 (ru) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940716B2 (en) * | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
EP2847215A1 (en) * | 2012-05-07 | 2015-03-18 | Synthes GmbH | Methods and devices for treating intervertebral disc disease |
JP6215338B2 (ja) * | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
CN106232122A (zh) * | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
BR112016015449A8 (pt) * | 2013-12-30 | 2020-06-09 | Lifesci Pharmaceuticals Inc | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos |
EP3466955B1 (en) * | 2014-01-13 | 2020-12-16 | Aurigene Discovery Technologies Limited | Method of preparing oxazolo[4,5-b]pyridine and thiazolo[4,5-b]pyridine derivatives as irak4 inhibitors for treating cancer |
EA039043B1 (ru) | 2015-04-22 | 2021-11-25 | Райджел Фармасьютикалз, Инк. | Пиразольные соединения и способ получения и применения данных соединений |
JP2018524365A (ja) * | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Irak−4阻害剤としての置換アザ化合物 |
US10059701B2 (en) * | 2015-09-18 | 2018-08-28 | Merck Patent Gmbh | Heteroaryl compounds as IRAK inhibitors and uses thereof |
EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
EP4252853A3 (en) | 2017-03-31 | 2023-12-13 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
JP2020524663A (ja) * | 2017-06-21 | 2020-08-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Irak4調節因子としてのイソインドリノン誘導体 |
JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス, インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
IL308364A (en) | 2017-10-31 | 2024-01-01 | Curis Inc | Compounds and preparations for the treatment of hematological disorders |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
JP2021508703A (ja) | 2017-12-26 | 2021-03-11 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
KR20210111252A (ko) | 2018-11-30 | 2021-09-10 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
WO2021041898A1 (en) | 2019-08-30 | 2021-03-04 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations |
US20230020507A1 (en) * | 2019-10-04 | 2023-01-19 | Parenchyma Biotech Inc. | Compound and use thereof in treating autoimmune diseases |
TW202136251A (zh) | 2019-12-17 | 2021-10-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
JP2023525047A (ja) | 2020-05-06 | 2023-06-14 | エイジャックス セラピューティクス, インコーポレイテッド | Jak2阻害薬としての6-ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
JP7422242B2 (ja) | 2020-09-30 | 2024-01-25 | 旭化成ファーマ株式会社 | マクロサイクル化合物 |
JP7433463B2 (ja) | 2020-09-30 | 2024-02-19 | 旭化成ファーマ株式会社 | ピリミジン含有含窒素二環化合物 |
TW202334139A (zh) | 2021-11-09 | 2023-09-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳氧基苯并咪唑及氮雜苯并咪唑 |
TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔5,4-b〕吡啶malt-1抑制劑 |
CN118239953A (zh) * | 2022-12-23 | 2024-06-25 | 中国科学院合肥物质科学研究院 | 用于治疗PI3Kγ介导的疾病的化合物及其用途 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5542990B2 (ru) * | 1972-01-27 | 1980-11-04 | ||
EP0907650B1 (en) * | 1996-06-27 | 2002-12-04 | Janssen Pharmaceutica N.V. | N- 4-(heteroarylmethyl)phenyl]-heteroarylamines |
BR9814956A (pt) | 1997-11-10 | 2000-10-03 | Bristol Myers Squibb Co | Inibidores de benzotiazol da tirosina cinase de proteìna |
JP2000086641A (ja) * | 1998-09-11 | 2000-03-28 | Kyorin Pharmaceut Co Ltd | 2−置換ベンゾチアゾール誘導体及びその製造法 |
IL164302A0 (en) * | 2002-03-29 | 2005-12-18 | Chiron Corp | Substituted benzazoles and use thereof as raf kinase inhibitors |
US20040023978A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Active salt forms with tyrosine kinase activity |
US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
US20070066577A1 (en) * | 2003-04-03 | 2007-03-22 | Hea Young Park Choo | Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same |
WO2005033105A2 (en) * | 2003-09-30 | 2005-04-14 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
MXPA06003607A (es) * | 2003-10-16 | 2006-06-05 | Chiron Corp | Quinazolinas, quinoxalinas, quinolinas e isoquinolinas 2.6-disubstituidas como inhibidores de la cinasa raf para el tratamiento del cancer. |
CA2543707A1 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP1674466A1 (en) | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
WO2007058482A1 (en) * | 2005-11-16 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel inhibitors of protein kinase |
CN101360707A (zh) * | 2005-11-23 | 2009-02-04 | 利亘制药公司 | 血小板生成素活性调节化合物和方法 |
US20090298897A1 (en) * | 2006-01-17 | 2009-12-03 | Marina Cools | Treatment of Inflammatory Disorders With Triazole Compounds |
WO2007089512A1 (en) * | 2006-01-27 | 2007-08-09 | Array Biopharma Inc. | Glucokinase activators |
US20080293785A1 (en) * | 2006-04-11 | 2008-11-27 | Connolly Peter J | Substituted benzothiazole kinase inhibitors |
CN101558059B (zh) * | 2006-08-11 | 2014-12-03 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
JP2010502717A (ja) * | 2006-09-07 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターロイキン1受容体関連キナーゼの調節物質 |
US20110021513A1 (en) * | 2006-09-07 | 2011-01-27 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
JP2008255024A (ja) * | 2007-04-02 | 2008-10-23 | Banyu Pharmaceut Co Ltd | ビアリールアミン誘導体 |
US20090258907A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
EP2444403A1 (en) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
US8420052B2 (en) * | 2008-07-24 | 2013-04-16 | Siemens Medical Solutions Usa, Inc. | Imaging agents useful for identifying AD pathology |
JP5177076B2 (ja) | 2008-07-28 | 2013-04-03 | 日産自動車株式会社 | 車両運転支援装置及び車両運転支援方法 |
TWI396689B (zh) * | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶10抑制劑之吡衍生物 |
US9067947B2 (en) * | 2009-01-16 | 2015-06-30 | Universal Display Corporation | Organic electroluminescent materials and devices |
EP2401273A1 (en) * | 2009-02-27 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
EP2408769A1 (en) * | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
US8765747B2 (en) * | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
WO2011110575A1 (en) * | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
WO2012035055A1 (en) * | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
MA39838B1 (fr) | 2014-04-04 | 2019-05-31 | Pfizer | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 |
-
2011
- 2011-11-18 CN CN201810959036.0A patent/CN108864151A/zh active Pending
- 2011-11-18 RU RU2013124101A patent/RU2632900C2/ru active
- 2011-11-18 MX MX2013005549A patent/MX344521B/es active IP Right Grant
- 2011-11-18 JP JP2013540089A patent/JP6005050B2/ja active Active
- 2011-11-18 PT PT141534933T patent/PT2730564T/pt unknown
- 2011-11-18 KR KR1020187024789A patent/KR20180099933A/ko not_active Application Discontinuation
- 2011-11-18 RU RU2017135541A patent/RU2017135541A/ru unknown
- 2011-11-18 MX MX2016016899A patent/MX366318B/es unknown
- 2011-11-18 PL PL14153493T patent/PL2730564T3/pl unknown
- 2011-11-18 WO PCT/US2011/061532 patent/WO2012068546A1/en active Application Filing
- 2011-11-18 RS RS20180735A patent/RS57375B1/sr unknown
- 2011-11-18 EP EP14153493.3A patent/EP2730564B1/en active Active
- 2011-11-18 KR KR1020137015153A patent/KR101903204B1/ko active IP Right Grant
- 2011-11-18 EP EP18161665.7A patent/EP3357915A1/en not_active Withdrawn
- 2011-11-18 HU HUE14153493A patent/HUE037860T2/hu unknown
- 2011-11-18 EP EP11791162.8A patent/EP2640708A1/en not_active Withdrawn
- 2011-11-18 CN CN2011800643922A patent/CN103298792A/zh active Pending
- 2011-11-18 ES ES14153493.3T patent/ES2672203T3/es active Active
-
2013
- 2013-05-16 MX MX2019008122A patent/MX2019008122A/es unknown
- 2013-12-20 US US14/137,318 patent/US9266874B2/en active Active
-
2016
- 2016-01-26 US US15/006,940 patent/US10030034B2/en active Active
- 2016-09-02 JP JP2016171817A patent/JP6316888B2/ja active Active
-
2018
- 2018-03-27 JP JP2018059583A patent/JP6726226B2/ja active Active
- 2018-06-22 US US16/015,925 patent/US10604533B2/en active Active
- 2018-09-07 HK HK18111558.1A patent/HK1252165A1/zh unknown
-
2020
- 2020-01-07 US US16/735,988 patent/US11186593B2/en active Active
-
2021
- 2021-10-28 US US17/513,093 patent/US11773110B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017135541A (ru) | Гетероциклические амины и их применения | |
USRE49556E1 (en) | Compounds and compositions as protein kinase inhibitors | |
HRP20210094T1 (hr) | POSTUPAK PRIPRAVE DERIVATIVA OKSAZOLO[4,5-b]PIRIDINA I TIAZOLO[4,5-b]PIRIDINA KAO INHIBITORA IRAK4 NAMIJENJENIH LIJEČENJU RAKA | |
ES2435798T3 (es) | Inhibidores de proteína cinasa | |
JP5805807B2 (ja) | N含有複素環式化合物 | |
HRP20181076T1 (hr) | Pirazolski derivati kao modulatori kalcijevih kanala aktiviranih oslobađanjem kalcija | |
KR101778354B1 (ko) | 헤테로환 유도체 및 의약 | |
Savall et al. | Discovery and SAR of 6-alkyl-2, 4-diaminopyrimidines as histamine H4 receptor antagonists | |
JP2013544256A5 (ru) | ||
HRP20170456T1 (hr) | Novi kondenzirani derivati pirimidina, namijenjeni inhibiranju aktivnosti tirozinske kinaze | |
AU2008240790A1 (en) | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 | |
TR201811976T4 (tr) | Mek inhibitörleri olarak heterosiklil bileşikleri. | |
BRPI0707189A2 (pt) | derivados de pirimidina utilizados como inibidores de pi-3 cinase | |
JP2012515789A5 (ru) | ||
JP2013531055A5 (ru) | ||
NZ597533A (en) | Apoptosis signal-regulating kinase inhibitors | |
WO2014167444A1 (en) | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | |
JP2009541268A5 (ru) | ||
Vasbinder et al. | Discovery and optimization of a novel series of potent mutant B-RafV600E selective kinase inhibitors | |
CA2697077A1 (en) | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | |
EP4136073A1 (en) | Substituted pyridines for the treatment of inflammatory diseases | |
AU2005300734A1 (en) | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | |
JP2011519845A5 (ru) | ||
HRP20161286T1 (hr) | Novi anti-invazivni spojevi | |
JP2012514577A5 (ru) |